Progression-Free Survival Under Immune Checkpoint Inhibitors for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
We created a predictive model on the basis of five simple biomarkers that may predict the efficacy of ICI regardless of PDL1 status. The presence of lung metastases, prolonged PFS1, low NLR, and smoking status are good prognostic factors, whereas the presence of bone metastases was associated with worse prognosis.
Authors
- L. Campion (ORCID: https://orcid.org/0000-0003-4903-0908)
- Laura Mezquita (ORCID: https://orcid.org/0000-0003-0936-7338)
- Judith Raimbourg (ORCID: https://orcid.org/0000-0002-2844-0257)
- Sandrine Hiret (ORCID: https://orcid.org/0000-0002-3789-8171)
- Ludovic Doucet (ORCID: https://orcid.org/0000-0001-6372-6261)
- Paul Boré
- Teresa Gorría
- Frédéric Bigot (ORCID: https://orcid.org/0000-0001-5890-107X)
- Jean‐Luc Raoul (ORCID: https://orcid.org/0000-0001-6305-8953)
- François Bocquet
- Margaux Geier
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université Nantes Angers Le Mans (FR)
- Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers (FR)
- Institut de Cancérologie de l'Ouest (FR)
- Hospital Clínic de Barcelona (ES)
- Centre Hospitalier Régional Universitaire de Brest (FR)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
- Nantes Université (FR)
Publication Details
- Journal
- Oncology and Therapy
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1007/s40487-025-00362-2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00